Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retina.

Tilavonemab (ABBV-8E12), a humanized anti-tau antibody, targets amino acids 25-30 near the tau protein's N-terminal end. It inhibits the uptake of tau aggregates by human and mouse neurons and diminishes brain atrophy, making it a potential tool in Alzheimer's disease research .

Valeroyl Salicylate is a non-steroidal anti-inflammatory agent and can lead to extension of lifespan, delays age-dependent decline of locomotor activity, and increases stress resistance.